{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:06:17Z","timestamp":1787238377830,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00495","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:44:55Z","timestamp":1599093895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer"],"prefix":"10.3389","volume":"7","author":[{"given":"Mariia","family":"Kiriukova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"de la Iglesia Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Panic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryana","family":"Bozhychko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartu","family":"Avci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"de-Madaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Capurso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasile","family":"Sandru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"B1","unstructured":"Globocan2018"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/10.suppl_4.S140","article-title":"Pancreatic cancer: clinical presentation, pitfalls and early clues","volume":"10","author":"DiMagno","year":"1999","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.clinbiochem.2017.07.011","article-title":"Biomarkers of cancer cachexia","volume":"50","author":"Loumaye","year":"2017","journal-title":"Clin Biochem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-018-0235-7","article-title":"Altered exocrine function can drive adipose wasting in early pancreatic cancer","volume":"558","author":"Danai","year":"2018","journal-title":"Nature."},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pan.2014.11.006","article-title":"Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review","volume":"15","author":"Ozola Zalite","year":"2015","journal-title":"Pancreatology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.dld.2012.05.017","article-title":"Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer","volume":"44","author":"Partelli","year":"2012","journal-title":"Dig Liver Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11912-012-0290-4","article-title":"The role of the FOLFIRINOX regimen for advanced pancreatic cancer","volume":"15","author":"Conroy","year":"2013","journal-title":"Curr Oncol Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1097\/MD.0000000000000198","article-title":"Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study","volume":"93","author":"Paniccia","year":"2014","journal-title":"Medicine."},{"key":"B14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jso.23392","article-title":"Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer","volume":"108","author":"Boone","year":"2013","journal-title":"J Surg Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pan.2018.10.003","article-title":"Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe","volume":"19","author":"Javed","year":"2018","journal-title":"Pancreatology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756284819877635","article-title":"Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine","volume":"12","author":"Scheithauer","year":"2019","journal-title":"Ther Adv Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1159\/000087495","article-title":"Pancreas 2000 - a new concept for education and development in pancreatology","volume":"5","author":"Gasslander","year":"2005","journal-title":"Pancreatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2017.03.022","article-title":"3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer","volume":"79","author":"Lutz","year":"2017","journal-title":"Eur J Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"79884","DOI":"10.18632\/oncotarget.20168","article-title":"Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study","volume":"8","author":"Muscaritoli","year":"2017","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0959-8049(99)00047-7","article-title":"Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC study group on quality of life","volume":"35","author":"Fitzsimmons","year":"1999","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000335478","article-title":"Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study","volume":"81","author":"Barret","year":"2011","journal-title":"Oncology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"189e200","DOI":"10.1016\/j.ejca.2016.05.011","article-title":"Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: a multicentre analysis","volume":"63","author":"Klute","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00495\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:44:56Z","timestamp":1599093896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00495\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":25,"alternative-id":["10.3389\/fmed.2020.00495"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00495","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"article-number":"495"}}